Bei Jing Shang Bao·2025-10-30 14:56Core Insights - Rongchang Biologics (688331) reported a significant increase in revenue for the first three quarters of 2025, achieving 1.72 billion yuan, which represents a year-on-year growth of 42.27%. However, the company recorded a net loss of 551 million yuan [1]. Financial Performance - The company's revenue for the first three quarters reached 1.72 billion yuan, marking a 42.27% increase compared to the previous year [1]. - The net profit attributable to the company was a loss of 551 million yuan [1]. Strategic Developments - The increase in product sales revenue was attributed to a substantial rise in sales and an optimization of the company's research and development pipeline, leading to a decrease in R&D expenses [1]. - Rongchang Biologics entered into a licensing agreement with Vor Bio, allowing Vor Bio exclusive rights to develop and commercialize the proprietary drug Tai Tasi Pu outside of Greater China, which resulted in reduced overseas clinical costs for the company [1].